...
首页> 外文期刊>Biochemistry >Structure of Toxoplasma gondii LDH1:Active-Site Differences from Human lactate Dehydrogenases and the Structural Basis for efficient APAD~+Use
【24h】

Structure of Toxoplasma gondii LDH1:Active-Site Differences from Human lactate Dehydrogenases and the Structural Basis for efficient APAD~+Use

机译:弓形虫LDH1的结构:人类乳酸脱氢酶的活性位点差异和有效APAD〜+用途的结构基础

获取原文
获取原文并翻译 | 示例
           

摘要

While within a human host the opportunistic pathogen Toxoplasma gondii relies heavily on glycolysis for NAD~+ regeneration,therefore represents an attractie therapeutic target.The tachyzoite stagelactatedehydrogenase(LDH1) from the parasite T.gondii has been crystallized in apo form and in ternary complexescontaining NAD~+ or the NAD~+-analogue 3-acetylpyridine adenine dinucleotide(APAD~+) and sulfate or the inhibitor oxalate.Comparison of the apo and ternary models showsan active-site loop that becomes ordered upon substrate binding.This active-site loop is five residues longer than in most LDHs and necessarily adopts a different conformation.While loop isomerizaiton is fully rate-limitin gin prototypical LDHs,kinetic data suggest that LDH1's rate islimited by chemical steps.The importance of charge neutralization in ligand bindign is supported by the complexes that have been crystallized as well as fluorescence quenching experiments performed with ligands at low and high pH.A methionine that replacesa serine residue and displaces an ordered water molecule often seen in LDH structures provides a structural explanation for reduced substrate inhibition.Superimposition of LDH1 with human muscle- and heart-specific LDH isoforms reveals differences in residues that line the active site that increase and heart-specific LDH isoforms reveals differences in residues that line the active sitethat increase LDH1's hydrophobicity.These differences will aid in designing inhibitors specific for LDH1 that may be useful in treating toxoplasmic encephalitis and other complications that arise in immune-compromised individuals.
机译:在人类宿主中,机会性病原体弓形虫严重依赖糖酵解来进行NAD〜+再生,因此代表了吸引性治疗靶标。来自寄生虫T.gondii的速殖子阶段乳化氢酶(LDH1)已以载脂蛋白形式和含NAD的三元复合物结晶。 〜+或NAD〜+类似物3-乙酰基吡啶腺嘌呤二核苷酸(APAD〜+)与硫酸盐或抑制剂草酸盐.apo和三元模型的比较显示了一个活性位点环,该活性位点环在与底物结合后变得有序。它比大多数LDHs长5个残基,并且必然采用不同的构象。环异构化是完全限制了杜松子酒原型LDHs的动力学,动力学数据表明LDH1的速率受化学步骤的限制。在低和高pH下用配体进行了结晶的配合物以及荧光猝灭实验。取代丝氨酸残基并置换LDH结构中经常出现的有序水分子的Line为减少底物抑制提供了结构性解释.LDH1与人肌肉和心脏特异性LDH亚型的叠加揭示了沿活性位点增加和心脏特异的LDH亚型揭示了活性位点上增加LDH1疏水性的残基的差异,这些差异将有助于设计LDH1特异性抑制剂,可用于治疗弓形虫性脑炎和免疫功能低下的个体引起的其他并发症。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号